Patent classifications
C12Q1/6869
Methods of producing ribosomal ribonucleic acid complexes
Provided are methods of producing a nucleic acid complex. In certain aspects, the methods include combining a sample including ribosomal RNA (rRNA) and a probe complement oligonucleotide with an oligonucleotide probe. The oligonucleotide probe includes a 3′ region complementary to a 3′ region of a rRNA, and a 5′ region complementary to the probe complement oligonucleotide. The combining is under conditions in which the 3′ region of the oligonucleotide probe hybridizes to the 3′ region of the rRNA and the 5′ region of the oligonucleotide probe hybridizes to the probe complement oligonucleotide, thereby producing a nucleic acid complex. In certain aspects, the methods find use in producing rRNA libraries that find use, e.g., in rRNA sequencing applications. Oligonucleotide probes, libraries thereof, compositions, and kits that find use, e.g., in practicing the methods of the present disclosure, are also provided.
Biomarkers for predicting tumor response to and toxicity of immunotherapy
The invention is directed to biomarkers for predicting a patient's response, both therapeutic and toxic, to immunotherapy.
Matrix arrays and methods for making same
A method of forming a polymer matrix array includes treating a surface within a well of a well array with a surface compound including a surface reactive functional group and a radical-forming distal group; applying an aqueous solution including polymer precursors to the well of the well array; and activating the radical-forming distal group of the surface coupling compound with an initiator and atom transfer radical polymerization (ATRP) catalyst to initiate radical polymerization of the polymer precursors within the well of the well array to form the polymer matrix array.
Matrix arrays and methods for making same
A method of forming a polymer matrix array includes treating a surface within a well of a well array with a surface compound including a surface reactive functional group and a radical-forming distal group; applying an aqueous solution including polymer precursors to the well of the well array; and activating the radical-forming distal group of the surface coupling compound with an initiator and atom transfer radical polymerization (ATRP) catalyst to initiate radical polymerization of the polymer precursors within the well of the well array to form the polymer matrix array.
Matrix arrays and methods for making same
A method of forming a polymer matrix array includes treating a surface within a well of a well array with a surface compound including a surface reactive functional group and a radical-forming distal group; applying an aqueous solution including polymer precursors to the well of the well array; and activating the radical-forming distal group of the surface coupling compound with an initiator and atom transfer radical polymerization (ATRP) catalyst to initiate radical polymerization of the polymer precursors within the well of the well array to form the polymer matrix array.
Methods, compositions, systems, apparatuses and kits for nucleic acid amplification
Novel methods of generating a localized population of immobilized clonal amplicons on a support are provided.
Methods, compositions, systems, apparatuses and kits for nucleic acid amplification
Novel methods of generating a localized population of immobilized clonal amplicons on a support are provided.
Antisense oligonucleotides for nucleotide deamination in the treatment of Stargardt disease
The invention relates to RNA editing oligonucleotides (EONs) that can bring about specific editing of a target nucleotide (adenosine) in a target RNA molecule in a eukaryotic cell, wherein said oligonucleotide is for use in the treatment of Stargardt disease, and more preferably for the deamination of target adenosines present in the ABCA4 pre-mRNA or ABCA4 mRNA.
Antisense oligonucleotides for nucleotide deamination in the treatment of Stargardt disease
The invention relates to RNA editing oligonucleotides (EONs) that can bring about specific editing of a target nucleotide (adenosine) in a target RNA molecule in a eukaryotic cell, wherein said oligonucleotide is for use in the treatment of Stargardt disease, and more preferably for the deamination of target adenosines present in the ABCA4 pre-mRNA or ABCA4 mRNA.
METHOD FOR DETERMINING A MEASURE CORRELATED TO THE PROBABILITY THAT TWO MUTATED SEQUENCE READS DERIVE FROM THE SAME SEQUENCE COMPRISING MUTATIONS
Disclosed is a computer-implemented method for determining a measure correlated to the probability that two mutated sequence reads derive from the same sequence comprising mutations. The method comprises receiving mutated sequence reads each corresponding to a subsequence of a sequence comprising mutations compared to a sequence not comprising mutations, applying a common minimizer function to each mutated sequence read, to determining minimizers for each mutated sequence read, determining positions of the one or more minimizers in each mutated sequence read, determining positions of mutations in each mutated sequence read, and for at least two mutated sequence reads with a common minimizer, counting the number of mutations with matching position and/or mismatching position when the respective minimizers are aligned. Also disclosed is a corresponding method for determining at least a portion of a sequence of at least one target template nucleic acid molecule.